• Fludarabine is used in various combinations with cyclophosphamide, mitoxantrone, dexamethasone and rituximab in the treatment of indolent non-Hodgkin's lymphomas. (wikipedia.org)
  • This phase II trial studies the side effect of busulfan, fludarabine phosphate, and post-transplant cyclophosphamide in treating patients with blood cancer undergoing donor stem cell transplant. (mdanderson.org)
  • Drugs used in chemotherapy, such as busulfan, fludarabine phosphate and cyclophosphamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. (mdanderson.org)
  • Secondary Objectives: To evaluate the effect of the Fludarabine-(etoposide, doxorubicin, vincristine, prednisone, cyclophosphamide) EPOCH regimen on host T cell depletion and myeloid depletion prior to allogeneic SCT. (drugpatentwatch.com)
  • BALLI-01 is a Phase 1/2a open-label dose-escalation trial evaluating the safety and clinical activity of UCART22 given at escalating dose levels after lymphodepletion (LD) with either fludarabine and cyclophosphamide (FC) or FC with alemtuzumab (FCA) in patients with relapsed or refractory acute lymphoblastic leukemia (r/r ALL). (cellectis.com)
  • Following high-dose chemotherapy with fludarabine plus cyclophosphamide, patients received an infusion of tisagenlecleucel. (ascopost.com)
  • Patients in the study will be treated with ALLO-501A in addition to ALLO-647 and lymphodepletion chemotherapy consisting of fludarabine and cyclophosphamide. (targetedonc.com)
  • The Company is also in the process of initiating the EXPAND trial, which is intended to demonstrate the contribution of ALLO-647 to the standard fludarabine/cyclophosphamide lymphodepletion regimen. (allogene.com)
  • The single-arm Phase 2 ALPHA2 trial in r/r LBCL will utilize a single dose of ALLO-501A at 120 million CAR+ cells with an intended lymphodepletion regimen (FCA90) comprised of fludarabine (30 mg/m 2 /day x 3 days) and cyclophosphamide (300 mg/m 2 /day x 3 days) plus ALLO-647 (90 mg). (allogene.com)
  • Patients will be randomized to receive the same single 120 million cell dose of ALLO-501A as in the ALPHA2 trial and either lymphodepletion with fludarabine and cyclophosphamide alone (control arm) or the same lymphodepletion regimen of the ALPHA2 trial (active arm). (allogene.com)
  • The BALLI-01 study is now enrolling patients after FCA (fludarabine, cyclophosphamide and alemtuzumab) lymphodepletion. (wapakdailynews.com)
  • Giving chemotherapy such as busulfan and fludarabine phosphate before a donor stem cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. (mdanderson.org)
  • Adding venetoclax to fludarabine/busulfan RIC transplant for high risk MDS and AML is feasible, safe, and active. (harvard.edu)
  • four othersreceived a reduced-intensity regimen consisting of fludarabine (Fludara),busulfan (Myleran), tacrolimus (Prograf), mycophenolate mofetil (CellCept), and4 Gy of total lymphoid radiation. (cancernetwork.com)
  • Patients will receive intensity modulated total marrow irradiation (TMI) at a dose of 9 Gy with standard myeloablative fludarabine/ i.v. targeted busulfan (FluBu) conditioning prior to allogeneic hematopoietic stem cell transplant (HSCT). (mycancergenome.org)
  • fludarabine 40 mg/m2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2, IV busulfan targeting a 4800μM/min/ day from day -5 through day -2, and ATG ( Thymoglobulin ®) at 0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1 (Only for recipients of stem cells from unrelated or mismatched donors). (mycancergenome.org)
  • All patients received a T-cell depletion protocol consisting of fludarabine, busulfan and thiotepa. (bjh.be)
  • All three of the responders failed multiple lines of prior therapy including chemotherapy, CD19-directed autologous CAR T cell therapy, and allogeneic stem cell transplant. (cellectis.com)
  • Part 2 of the CASSIOPEIA trial in 866 patients with newly diagnosed multiple myeloma demonstrated benefit for maintenance daratumumab after treatment with bortezomib, thalidomide, and dexamethasone (V-Td) with or without daratumumab and autologous stem cell transplant. (ascopost.com)
  • ELARA was a phase II, international, single-arm trial that enrolled 98 patients with follicular lymphoma treated with at least two prior lines of therapy or for whom autologous stem cell transplant was not effective. (ascopost.com)
  • Five patients received autologous HSCT: threemarrow and two peripheral blood stem cells. (cancernetwork.com)
  • Six patients relapsed, includingall five autologous and one allogeneic recipients. (cancernetwork.com)
  • Expanded natural killer cells killed both allogeneic and autologous primary myeloma cells avidly via a perforin-mediated mechanism in which the activating receptor NKG2D, natural cytotoxicity receptors, and DNAX-accessory molecule-1 played a central role. (haematologica.org)
  • This article contains highlights of "Guidelines for Pre- allogeneic or autologous, depending on the source of venting Opportunistic Infections among Hematopoi- the transplanted hematopoietic progenitor cells. (cdc.gov)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • Recent clinical studies have shown that highly immunosuppressive yet non-myeloablative doses of fludarabine-based chemotherapy can result in alloengraftment. (drugpatentwatch.com)
  • To determine the efficacy of a novel conventional chemotherapy regimen (Fludarabine-EPOCH) in the setting multiple myeloma. (drugpatentwatch.com)
  • [ 2 ] Options for second-line therapy in patients with relapsed/refractory disease include chemotherapy-free regimens with biologic targeted agents such as covalent Bruton tyrosine kinase (BTK) inhibitors, lenalidomide,venetoclax, and chimeric antigen receptor (CAR) T-cell therapy. (medscape.com)
  • Although combination chemotherapy regimens, including the nucleoside analogue fludarabine, were once the most commonly used first-line therapy in CLL, non-chemotherapy regimens (eg, with Bruton tyrosine kinase [BTK] inhibitors) are currently preferred in most cases. (medscape.com)
  • Allo-HSCT includes administration of a chemotherapy-based conditioning regimen (myelo-ablative or non-myelo-ablative), followed by infusion of alloreactive haematopoietic stem cells, with the aim of inducing an active immunological anti-tumoral effect. (biomedcentral.com)
  • The CAR T cells are gene-edited so that CD52, which is a cell surface protein that's on immune cells, is removed from the CAR T cells and that actually allows us to also give an antibody against CD52 as part of the conditioning chemotherapy regimen, which ALLO-647. (targetedonc.com)
  • Although the intended target is the malignant cells of Hodgkin lymphoma, the effects of chemotherapy on normal cells of the body are considerable and account for the adverse effects observed with these agents. (medscape.com)
  • Cancer chemotherapy is based on an understanding of tumor cell growth and of how drugs affect this growth. (medscape.com)
  • This difference allows normal cells to recover more quickly than malignant ones after chemotherapy and is the rationale behind current cyclic dosage schedules. (medscape.com)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • Thus, we studied the safety, efficacy, and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte infusion (DLI). (frontiersin.org)
  • The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. (frontiersin.org)
  • CONCLUSION: These data demonstrate the feasibility of allogeneic orautologous HSCT in heavily pretreated lymphoma patients who also receivedtositumomab/iodine-131 tositumomab. (cancernetwork.com)
  • In patients having these risk factors, consolidative allo-HSCT after CAR T-cell therapy may prolong LFS. (biomedcentral.com)
  • Allo-HSCT provides optimal clinical benefit in patients with MRD-negative complete remission, typically within three months after CAR T-cell therapy. (biomedcentral.com)
  • Herein, we summarize the clinical data on consolidative allo-HSCT after anti-CD19 CAR T-cell therapy, as well as the potential factors associated with allo-HSCT benefit. (biomedcentral.com)
  • The combination of CAR T-cell therapy and allo-HSCT has been suggested to reduce the relapse rate of leukemia. (biomedcentral.com)
  • Recently published data suggest that enteral nutrition (EN), given as systematic artificial nutrition support, could decrease grade III-IV graft-versus-host disease (GVHD) and infectious events, which are associated with early toxicity after allo-HSCT and then have an impact on early transplant-related mortality (D100 mortality). (biomedcentral.com)
  • We report on the NEPHA trial: an open-label, prospective, randomised, multi-centre study on two parallel groups, which has been designed to evaluate the effect of EN compared to PN on early toxicity after an allo-HSCT procedure. (biomedcentral.com)
  • Two hundred forty patients treated with allo-HSCT for a haematological malignancy will be randomly assigned to two groups to receive either EN or PN. (biomedcentral.com)
  • Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. (mdanderson.org)
  • In this prospective phase II trial, we assessed the efficacy and toxicity of treosulfan, fludarabine, and 2 Gy total body irradiation (TBI) as conditioning for allogeneic HCT in patients with MDS or AML. (bvsalud.org)
  • Patients received 14 g/m(2)/day treosulfan i.v. on days -6 to -4, 30 mg/m(2)/day fludarabine i.v. on days -6 to -2, and 2 Gy TBI on day 0, followed by infusion of hematopoietic cells from related (n = 27) or unrelated (n = 69) donors . (bvsalud.org)
  • In conclusion, treosulfan, fludarabine, and low- dose TBI provided effective conditioning for allogeneic HCT in patients with MDS or AML and resulted in low relapse incidence , regardless of cytogenetic risk . (bvsalud.org)
  • The profound lymphopenia caused by fludarabine renders patients susceptible to transfusion-associated graft versus host disease, an oftentimes fatal complication of blood transfusion. (wikipedia.org)
  • For this reason, all patients who have ever received fludarabine should only be given irradiated blood components. (wikipedia.org)
  • Fludarabine is associated with the development of severe autoimmune hemolytic anemia in a proportion of patients. (wikipedia.org)
  • Difficulties are often encountered when harvesting peripheral blood stem cells from patients previously treated with fludarabine. (wikipedia.org)
  • Donor chimerism was stabilized after transfusion of the transduced cells in all patients treated. (frontiersin.org)
  • Patients were monitored for donor engraftment of myeloid and lymphoid cells, for clinical response by serial imaging, and for immunologic response by in vitro isolation of donor-derived CD8 + CTLs recognizing recipient minor histocompatibility (H) antigens. (aacrjournals.org)
  • Clones from three patients with a partial response or stable disease recognized antigens expressed on renal cell carcinoma tumor cells. (aacrjournals.org)
  • Compared to the last clinical update on BALLI-01 at ASH 2021, the webcast presented data from five additional patients who received UCART22 at dose level 3 (DL3) 5x106 cells/kg after lymphodepletion with FCA. (cellectis.com)
  • These treatment responses in combination with the safety data are very encouraging for patients with r/r B-cell ALL who have limited, if any, treatment options, especially for those who have failed prior CD19 directed CAR T-cell therapy and allogeneic stem cell transplant', said Nitin Jain, M.D., The University of Texas MD Anderson Cancer Center, Department of Leukemia, and coordinating investigator for the BALLI-01 study. (cellectis.com)
  • Determine the safety of LMB-2 immunotoxin-treated, selectively-depleted donor T cells, administered after allogeneic PBSCT, in these patients. (knowcancer.com)
  • T cell preparation: Patients and donors undergo apheresis to obtain peripheral blood mononuclear cells (PBMCs), which are expanded in culture. (knowcancer.com)
  • LMB-2 immunotoxin-treated, selectively-depleted donor T cells: Patients receive LMB-2 immunotoxin-treated, selectively-depleted donor T cells IV over 30-60 minutes on approximately day 28. (knowcancer.com)
  • Cohorts of 3-6 patients receive escalating dose of LMB-2 immunotoxin-treated, selectively-depleted donor T cells until the maximum tolerated dose (MTD) is determined. (knowcancer.com)
  • In 15 to 20% of patients, plasma cells secrete only Bence Jones protein. (merckmanuals.com)
  • Tisagenlecleucel achieved complete responses in two-thirds of adults with heavily pretreated follicular lymphoma in the single-arm, phase II ELARA trial.2 The overall response rate in these patients with relapsed/refractory disease was 86%, and the complete response rate was 66% on treatment with tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell therapy. (ascopost.com)
  • The majority of cytokine-release syndrome events (75%) and 100% of the immune effector cell-associated neurotoxicity events were reported in patients with bulky disease. (ascopost.com)
  • In March, the Company announced that no safety concerns nor evidence of GvHD had been reported in the first three patients treated at dose level 1 (30×10 6 cells per infusion) of CYAD-211 in the IMMUNICY-1 trial. (pharmiweb.com)
  • The clinical presentation of patients with aplastic anemia includes signs and symptoms related to the decrease in bone marrow production of hematopoietic cells. (medscape.com)
  • A conditioning regimen consisting of fludarabine, total body radiation 450 cGy and alemtuzumab (CD52 mAb) was used for 15 patients. (nih.gov)
  • Although anti-CD19 chimeric antigen receptor (CAR) T-cell therapy shows good efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL), it fails to improve long-term leukemia-free survival (LFS). (biomedcentral.com)
  • Recent clinical data indicate that patients with complex karyotypes, adverse genes, and high pre-infusion minimal residual disease (MRD) by flow cytometry in the bone marrow, were at high risk of relapse after CAR T-cell therapy. (biomedcentral.com)
  • Finally, and most importantly, we provide recommendations for the assessment and management of r/r B-ALL patients undergoing anti-CD19 CAR T-cell therapy. (biomedcentral.com)
  • Patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) often have clinicopathological characteristics associated with poor prognosis, such as high tumor burden and high-risk gene mutations. (biomedcentral.com)
  • Patients must have a related or unrelated peripheral blood stem cell donor as follows: 1. (mycancergenome.org)
  • Nephrotic range proteinuria was identified in 17 of the patients, which is the largest cohort reported to date following allogeneic HCT. (ashpublications.org)
  • Patients with CLL typically have a higher-than-normal white blood cell count, which is determined by a complete blood count (CBC). (medscape.com)
  • Results Natural killer cells from healthy donors and myeloma patients expanded a median of 804- and 351-fold, respectively, without significant T-cell expansion. (haematologica.org)
  • OBJECTIVES: To describe the morphologic characteristics of skin lesions, extent of extracutaneous disease, and outcomes in patients with neonatal presentation of Langerhans cell histiocytosis (LCH), and to examine clinical predictors of disease prognosis. (thedoctorsdoctor.com)
  • Currently, there are no known risk factors to identify paediatric patients who may be at a greater risk of this complication when patients are treated with an ex vivo T-cell depletion protocol beforehand. (bjh.be)
  • In this retrospective analysis, paediatric AML/ALL patients who were treated with an ex vivo T-cell depleting protocol and were subsequently treated with aHSCT, being under the age of 9 and having a CD8+ concentration ≥150 μL was associated with a higher risk of graft failure. (bjh.be)
  • An investigation of ALLO-501A for the treatment of patients with large B-cell lymphoma is occurring in the phase 2 ALPHA2 study (NCT04416984), which aims to include 100 patients. (targetedonc.com)
  • SOUTH SAN FRANCISCO, Calif. , Oct. 06, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics , Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the initiation of the potentially pivotal Phase 2 clinical trial of ALLO-501A (ALPHA2 trial) in patients with relapsed/refractory (r/r) large B-cell lymphoma (LBCL). (allogene.com)
  • Gühne F , Seifert P , Theis B , Steinert M , Freesmeyer M , Drescher R . PSMA-PET/CT in Patients with Recurrent Clear Cell Renal Cell Carcinoma: Histopathological Correlations of Imaging Findings. (mitteldeutsches-krebszentrum.de)
  • Cellectis plans to use the net proceeds of the funds to focus on the development of its pipeline of allogeneic CAR T-cell product candidates UCART22, UCART20x22 and UCART123, the Company decided to stop enrollment and treatment of patients with UCARTCS1. (wapakdailynews.com)
  • UCART22 is an allogeneic CAR T-cell product candidate targeting CD22 and is being evaluated in patients with r/r B-ALL in the BALLI-01 Phase 1/2a clinical study. (wapakdailynews.com)
  • UCART20x22 is Cellectis' first allogeneic dual CAR T-cell product candidate targeting both CD20 and CD22 and is being evaluated in patients with r/r NHL in the NATHALI-01 Phase 1/2a clinical study. (wapakdailynews.com)
  • Because of its immunosuppressive effects, fludarabine is also used in some conditioning regimens prior to allogeneic stem cell transplant. (wikipedia.org)
  • Hematopoietic stem cell transplant. (mayoclinic.org)
  • http://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant/stem-cell-fact-sheet. (mayoclinic.org)
  • A 17-year-old woman with severe systemic lupus erythematosus and secondary myelodysplastic syndrome received an unrelated T-cell depleted bone marrow transplant. (cdc.gov)
  • Transplant Cell Ther 2021. (harvard.edu)
  • Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
  • Prior anti-CD19 therapy or allogeneic transplant was not allowed. (ascopost.com)
  • A woman with human immunodeficiency virus (HIV) who received a cord blood stem cell transplant to treat acute myeloid leukemia has had no detectable levels of HIV for 14 months, despite cessation of antiretroviral therapy, according to research presented at the Conference on Retroviruses and. (ascopost.com)
  • The impacts of nutritional support should exceed the limits of nutritional status improvement: EN may directly reduce immunological and infectious events, as well as decrease early transplant-related morbidity and mortality. (biomedcentral.com)
  • Although further prospective research is required to validate these findings, these results highlight the significance of pre-existing cellular immunity and support the use of T-cell population analysis in the pre-transplant patient workup. (bjh.be)
  • Frederick Locke, MD, a medical oncologist and translational researcher in the Department of Blood and Marrow Transplant and Cellular Immunotherapy at Moffitt Cancer Center, explains the allogeneic CD19-directed chimeric antigen receptor (CAR) T-cell therapies, ALLO-501 and ALLO-501A, and how they work. (targetedonc.com)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
  • Transduced cells were transfused either after day +60 (matched donors) or on day +42 (haploidentical donors). (frontiersin.org)
  • Objectives: Primary Objectives: To induce cellular and humoral immunity in allogeneic stem cell donors and recipients against the unique idiotype expressed by the recipient's myeloma. (drugpatentwatch.com)
  • Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). (mdanderson.org)
  • Our lead shRNA-based allogeneic candidate, CYAD-211, which is currently being evaluated in the Phase 1 IMMUNICY-1 trial for the treatment of multiple myeloma, has shown no safety concerns nor evidence of Graft-versus-Host Disease (GvHD) at dose level 1. (pharmiweb.com)
  • The track locus is removed so that the T cell receptor is not expressed and therefore, the cells are unlikely to cause graft-versus-host disease. (targetedonc.com)
  • or dose level 3 (DL3) 3.30x106 cells/kg after lymphodepletion with FC ([n=8], DL1 - DL3) or FCA ([n=9], DL2 & DL2i). (cellectis.com)
  • High pre-lymphodepletion lactate dehydrogenase, low pre-lymphodepletion platelet count, absence of fludarabine in lymphodepletion, persistent leukemic sequence by high throughput sequencing in bone marrow after CAR T-cell infusion, and early loss of CAR T cells have also been linked to relapse after CAR T-cell therapy. (biomedcentral.com)
  • The immunosuppressive agent alemtuzumab is a DNA-derived, humanized monoclonal antibody directed against the panlymphocyte, cell-surface antigen CD52 ( 1 ). (cdc.gov)
  • Alemtuzumab was added to the LD regimen to sustain host T-cell and Natural Killer (NK) cell depletion and to promote UCART22 cell expansion and persistence. (cellectis.com)
  • Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the "Company"), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced an update on its financial results and recent business developments for the fiscal quarter ended March 31, 2021. (pharmiweb.com)
  • CYAD-211 is an investigational, shRNA-based allogeneic CAR T candidate engineered to co-express a BCMA-targeting chimeric antigen receptor and a single shRNA, which interferes with the expression of the CD3ζ component of the T-cell receptor (TCR) complex. (pharmiweb.com)
  • Frederick Locke, MD, discuss 2 allogeneic CD19-directed chimeric antigen receptor T-cell agents for the treatment of relapsed or refractory large B-cell lymphoma. (targetedonc.com)
  • Secondary endpoints will compare EN and PN with regards to the main haematological, infectious and nutritional outcomes. (biomedcentral.com)
  • Investigating this, a Spanish research group retrospectively analysed risk factors and outcomes in 148 T-cell deprived haploidentical transplantations. (bjh.be)
  • Among seven allogeneic transplants,three received matched related peripheral blood stem cells and four receivedmatched unrelated marrow (n = 3) or peripheral blood (n = 1) stem cells.Allogeneic recipients received tacrolimus and methotrexate for graft-vs-hostdisease prophylaxis. (cancernetwork.com)
  • Although T-cell depletion (TCD) reduces the risk of GVHD after a myeloablative conditioning regimen, it is associated with an increased risk of graft failure. (qub.ac.uk)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
  • Blood-forming stem cell transplants. (mayoclinic.org)
  • To determine whether antigen-specific immunity, induced in the stem cell donor, can be passively transferred to the allogeneic SCT recipient in the setting of a non-myeloablative conditioning regimen. (drugpatentwatch.com)
  • The drug is approved for the treatment of refractory B-cell chronic lymphocytic leukemia ( 2 ) and also has been used after stem cell ( 3 ) and organ transplantations ( 4 ). (cdc.gov)
  • The theoretical basis for marrow failure includes primary defects in or damage to the stem cell or the marrow microenvironment. (medscape.com)
  • External insults (eg, infections, radiation, drugs) may disrupt stem cell homeostasis in marrow environment, leading to altered growth. (medscape.com)
  • On day 0, the stem cell product will be infused according to BMT unit policy. (mycancergenome.org)
  • Various drug combinations have been used with stem-cell rescue. (medscape.com)
  • and hematopoietic stem cell safety. (cdc.gov)
  • Antibody- and T-cell-based approaches to targeting of B-cell maturation antigen have shown efficacy. (merckmanuals.com)
  • In first quarter 2021, the Company initiated enrollment in dose level 2 (100×10 6 cells per infusion). (pharmiweb.com)
  • It is generally used as its 5-O-phosphorylated form known as fludarabine phosphate, sold under the brand name Fludara among others. (wikipedia.org)
  • Fludarabine is generally administered as its 5-O-phosphorylated form known as fludarabine phosphate, which is rapidly dephosphorylated to fludarabine in the plasma. (wikipedia.org)
  • Donor immunization with myeloma Id in the setting of a non-myeloablative allogeneic SCT may represent a novel strategy for the treatment of multiple myeloma. (drugpatentwatch.com)
  • We have previously shown an advantage of a myeloablative conditioning regimen with reduced toxicity (Fludarabine 150mg/m 2 , Treosulfan 42g/m 2 , FluTreo) compared to a reduced intensity regimen. (confex.com)
  • MDS are clonal disorders of myeloid stem cells. (medscape.com)
  • We have therefore examined whether TCD compromises engraftment using a fludarabine-based conditioning regimen. (qub.ac.uk)
  • CD34-selection of stem cells reduces the risk of aGvHD, but also leads to increased infectious complications and relapse. (frontiersin.org)
  • Even with a reduction in treatment related mortality, success with allogeneic SCT is limited by a significant risk of relapse. (drugpatentwatch.com)
  • The other three allogeneic recipients died from either graft-vs-hostdisease, relapse, or acetaminophen-induced hepatic necrosis. (cancernetwork.com)
  • Early loss or exhaustion of CAR T cells, selection of CD19-negative clones, downregulation of CD19 expression, lineage switch of leukemia, and tumor microenvironment are important factors contributing to relapse after CAR T-cell therapy [ 9 , 10 ]. (biomedcentral.com)
  • Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (merckmanuals.com)
  • Diagnosis typically requires demonstration of M-protein (sometimes present in urine and not serum but rarely absent entirely) and/or light-chain proteinuria, and excessive plasma cells in the bone marrow. (merckmanuals.com)
  • Lesions are caused by bone replacement by expanding plasmacytomas or by cytokines that are secreted by malignant plasma cells that activate osteoclasts and suppress osteoblasts, leading to bone loss. (merckmanuals.com)
  • Low-power view of hematoxylin-eosin-stained bone marrow showing hypocellularity, with increased adipose tissue and decreased hematopoietic cells in the marrow space. (medscape.com)
  • These mice are devoid of endogenous natural killer and T-cell activity and were used to determine whether adoptively transferred expanded natural killer cells could inhibit myeloma growth and myeloma-associated bone destruction. (haematologica.org)
  • The transferred, expanded natural killer cells proliferated in vivo in an interleukin-2 dose-dependent fashion, persisted up to 4 weeks, were readily detectable in the human bone, inhibited myeloma growth and protected bone from myeloma-induced osteolysis. (haematologica.org)
  • Multiple myeloma (MM) is a malignant plasma cell disorder with debilitating symptoms related to anemia, immunosuppression, bone destruction, and renal failure. (haematologica.org)
  • Leukemia is a group of clonal diseases derived from a single cell with a genetic alteration in bone marrow or peripheral lymphoid tissue, and each type is determined by the specificity of the source cell. (sld.cu)
  • A bone marrow cancer that is characterized by under production of white blood cells, red blood cells and platelets. (jax.org)
  • High and durable response rates were seen with the CAR T-cell therapy brexucabtagene autoleucel in heavily pretreated adults with relapsed/refractory B-cell-precursor acute lymphoblastic leukemia (B-ALL), according to results of the phase I/II ZUMA-3 study. (ascopost.com)
  • Phase 1 clinical trial of CRISPR-engineered CAR19 universal T cells for treatment of children with refractory B cell leukemia. (sciencenet.cn)
  • UCART22 is currently the most advanced allogeneic CAR T-cell product in development for relapsed or refractory B-cell acute lymphoblastic leukemia. (wapakdailynews.com)
  • Total body irradiation was not used, and the median total number of CD34 + cells infused was 7.85 x 10 6 /kg. (bjh.be)
  • ALLO-501 and ALLO-501A are off-the-shelf allogeneic CD19-directed CAR T-cell therapies. (targetedonc.com)
  • NEW YORK, May 04, 2023 (GLOBE NEWSWIRE) -- Cellectis (the "Company") (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today provided a business update and announced its results for the three-month period ending March 31, 2023. (wapakdailynews.com)
  • We tested whether natural killer cells expanded by co-culture with K562 cells transfected with 41BBL and membrane-bound interleukin-15 could kill myeloma cells with a high-risk gene expression profile in vitro and in a unique model which recapitulates human myeloma. (haematologica.org)
  • Adoptive transfer of expanded natural killer cells inhibited the growth of established OPM2 and high-risk primary myeloma tumors grown in the murine model. (haematologica.org)
  • CD8 + CTL-recognizing minor H antigens on tumor cells can be isolated posttransplant and could contribute to the graft- versus -tumor effect. (aacrjournals.org)
  • Investigators will assess LP-284 as a treatment for those with B-cell non-Hodgkin lymphoma in a phase 1 trial. (cancernetwork.com)
  • After cells divide, they enter a period of growth (ie, phase G1), followed by DNA synthesis (ie, phase S). The next phase is a premitotic phase (ie, G2), then finally a mitotic cell division (ie, phase M). (medscape.com)
  • We are proud to initiate the industry's first potentially pivotal Phase 2 trial for an allogeneic CAR T product. (allogene.com)